$LIXT
LIXTE BIOTECHNOLOGY HOLDINGS, INC.

2024 Q4 Form 10-Q Financial Statement

#000149315224044810 Filed on November 12, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $328.5K
YoY Change -63.16%
% of Gross Profit
Research & Development $361.6K
YoY Change 172.96%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $983.3K
YoY Change -4.0%
Operating Profit -$983.3K
YoY Change -4.0%
Interest Expense $1.049K
YoY Change 275.99%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$986.0K
YoY Change -3.21%
Income Tax
% Of Pretax Income
Net Earnings -$986.0K
YoY Change -3.21%
Net Earnings / Revenue
Basic Earnings Per Share -$0.44
Diluted Earnings Per Share -$0.44
COMMON SHARES
Basic Shares Outstanding 2.249M shares 2.249M shares
Diluted Shares Outstanding 2.249M shares

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.638M
YoY Change -67.92%
Cash & Equivalents $1.638M
Short-Term Investments
Other Short-Term Assets $51.34K
YoY Change -60.23%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $1.689M
YoY Change -67.74%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $6.930K
YoY Change
Total Long-Term Assets $6.928K
YoY Change
TOTAL ASSETS
Total Short-Term Assets $1.689M
Total Long-Term Assets $6.928K
Total Assets $1.696M
YoY Change -67.6%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $72.86K
YoY Change -67.06%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $329.0K
YoY Change 5.52%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $329.0K
Total Long-Term Liabilities $0.00
Total Liabilities $329.0K
YoY Change 5.52%
SHAREHOLDERS EQUITY
Retained Earnings -$51.45M
YoY Change 8.43%
Common Stock $225.00
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $1.367M
YoY Change
Total Liabilities & Shareholders Equity $1.696M
YoY Change -67.6%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$986.0K
YoY Change -3.21%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$957.6K
YoY Change 1.75%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities -957.6K
Cash From Investing Activities
Cash From Financing Activities
Net Change In Cash -957.6K
YoY Change -143.68%
FREE CASH FLOW
Cash From Operating Activities -$957.6K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
usd
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001335105
CY2023Q4 LIXT Advances On Research And Development Contract Services
AdvancesOnResearchAndDevelopmentContractServices
78016 usd
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
17116 usd
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
10000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
4308620 usd
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39717
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-2903526
dei Entity Address Address Line1
EntityAddressAddressLine1
680 East Colorado Boulevard
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 180
dei Entity Address City Or Town
EntityAddressCityOrTown
Pasadena
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
91101
dei City Area Code
CityAreaCode
(631)
dei Local Phone Number
LocalPhoneNumber
830-7092
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
2249290 shares
CY2023Q4 us-gaap Cash
Cash
4203488 usd
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2249290 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2249290 shares
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
283053 usd
CY2024Q3 LIXT Legal Fees Relating To Patents And Licensing
LegalFeesRelatingToPatentsAndLicensing
45416 usd
CY2023Q3 LIXT Legal Fees Relating To Patents And Licensing
LegalFeesRelatingToPatentsAndLicensing
178012 usd
CY2024Q3 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
293158 usd
CY2023Q3 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
357681 usd
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
361630 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
132487 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
1024181 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-983257 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1024181 usd
CY2024Q3 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
1437 usd
CY2023Q3 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
5809 usd
CY2024Q3 us-gaap Interest Expense
InterestExpense
1049 usd
CY2023Q3 us-gaap Interest Expense
InterestExpense
279 usd
CY2024Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-3161 usd
CY2023Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-109 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-986030 usd
CY2024Q3 LIXT Advances On Research And Development Contract Services
AdvancesOnResearchAndDevelopmentContractServices
usd
CY2023Q4 us-gaap Deferred Costs
DeferredCosts
usd
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
usd
LIXT Share Based Compensation Included In Research And Development Cost
ShareBasedCompensationIncludedInResearchAndDevelopmentCost
usd
LIXT Share Based Compensation Included In Research And Development Cost
ShareBasedCompensationIncludedInResearchAndDevelopmentCost
usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
usd
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
CY2023Q3 us-gaap Deferred Offering Costs
DeferredOfferingCosts
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
dei Document Type
DocumentType
10-Q
dei Entity Registrant Name
EntityRegistrantName
LIXTE BIOTECHNOLOGY HOLDINGS, INC.
dei Entity Small Business
EntitySmallBusiness
true
CY2024Q3 us-gaap Cash
Cash
1637627 usd
CY2024Q3 us-gaap Prepaid Insurance
PrepaidInsurance
17081 usd
CY2024Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
34256 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
1688964 usd
CY2024Q3 us-gaap Deferred Costs
DeferredCosts
6928 usd
CY2024Q3 us-gaap Assets
Assets
1695892 usd
CY2023Q4 us-gaap Assets
Assets
4308620 usd
CY2024Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
72859 usd
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
156758 usd
CY2024Q3 LIXT Research And Development Contract Liabilities Current
ResearchAndDevelopmentContractLiabilitiesCurrent
256097 usd
CY2023Q4 LIXT Research And Development Contract Liabilities Current
ResearchAndDevelopmentContractLiabilitiesCurrent
157100 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
328956 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
313858 usd
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
3500000 usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
3500000 usd
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2249290 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2249290 shares
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
225 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
225 usd
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
49316710 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
48976265 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-51449999 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-48481728 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
1366936 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
3994762 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1695892 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4308620 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
356001 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
907069 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1398042 usd
LIXT Legal Fees Relating To Patents And Licensing
LegalFeesRelatingToPatentsAndLicensing
192239 usd
LIXT Legal Fees Relating To Patents And Licensing
LegalFeesRelatingToPatentsAndLicensing
835362 usd
us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
1168582 usd
us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
1081893 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
691402 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
749029 usd
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
983257 usd
us-gaap Operating Expenses
OperatingExpenses
2959292 usd
us-gaap Operating Expenses
OperatingExpenses
4064326 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-2959292 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-4064326 usd
us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
6529 usd
us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
13538 usd
us-gaap Interest Expense
InterestExpense
12389 usd
us-gaap Interest Expense
InterestExpense
6088 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-3119 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
2102 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-1018760 usd
us-gaap Net Income Loss
NetIncomeLoss
-2968271 usd
us-gaap Net Income Loss
NetIncomeLoss
-4054774 usd
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.44
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.44
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.49
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.49
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.32
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.32
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.25
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.25
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2249290 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2249290 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2074938 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2074938 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2249290 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2249290 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1803466 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1803466 shares
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
2246139 usd
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
106827 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-986030 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
1366936 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
3994762 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
340445 usd
us-gaap Net Income Loss
NetIncomeLoss
-2968271 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
1366936 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
2692534 usd
CY2023Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
3137039 usd
CY2023Q3 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
41 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
112106 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-1018760 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
4922960 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
5165227 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
5165227 usd
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
3137039 usd
us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
41 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
6281 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
669146 usd
us-gaap Net Income Loss
NetIncomeLoss
-4054774 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
4922960 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
4922960 usd
us-gaap Net Income Loss
NetIncomeLoss
-2968271 usd
us-gaap Net Income Loss
NetIncomeLoss
-4054774 usd
LIXT Share Based Compensation Included In General And Administrative Cost
ShareBasedCompensationIncludedInGeneralAndAdministrativeCost
340445 usd
LIXT Share Based Compensation Included In General And Administrative Cost
ShareBasedCompensationIncludedInGeneralAndAdministrativeCost
669146 usd
LIXT Increase Decrease In Advances On Research And Development Contract Services
IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices
-78016 usd
LIXT Increase Decrease In Advances On Research And Development Contract Services
IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices
-69002 usd
us-gaap Increase Decrease In Prepaid Insurance
IncreaseDecreaseInPrepaidInsurance
-35 usd
us-gaap Increase Decrease In Prepaid Insurance
IncreaseDecreaseInPrepaidInsurance
-25994 usd
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
24256 usd
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
17460 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-90827 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-8593 usd
LIXT Increase Decrease In Research And Development Contract Liabilities
IncreaseDecreaseInResearchAndDevelopmentContractLiabilities
98997 usd
LIXT Increase Decrease In Research And Development Contract Liabilities
IncreaseDecreaseInResearchAndDevelopmentContractLiabilities
-74457 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2565861 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3391142 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
3137039 usd
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
41 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
6281 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3143361 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2565861 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-247781 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
4203488 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
5353392 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1637627 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
5105611 usd
CY2024Q3 us-gaap Deferred Offering Costs
DeferredOfferingCosts
6928 usd
us-gaap Interest Paid Net
InterestPaidNet
12389 usd
us-gaap Interest Paid Net
InterestPaidNet
6088 usd
CY2023Q2 LIXT Nasdaq Listing Maintaining Minimum Net Stockholders Equity
NasdaqListingMaintainingMinimumNetStockholdersEquity
2500000 usd
us-gaap Net Income Loss
NetIncomeLoss
-2968271 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2565861 usd
CY2024Q3 us-gaap Cash
Cash
1637627 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_846_eus-gaap--UseOfEstimates_zMqNoLUwsJSd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_zf0cK7THKte2">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Some of those judgments can be subjective and complex, and therefore, actual results could differ materially from those estimates under different assumptions or conditions. Management bases its estimates on historical experience and on various assumptions that are believed to be reasonable in relation to the financial statements taken, as a whole, under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Management regularly evaluates the key factors and assumptions used to develop the estimates utilizing currently available information, changes in facts and circumstances, historical experience, and reasonable assumptions. After such evaluations, if deemed appropriate, those estimates are adjusted accordingly. Actual results could differ from those estimates. Significant estimates include those related to assumptions used in the calculation of accruals for clinical trial costs and other potential liabilities, and valuing equity instruments issued for services.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q3 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000 usd
CY2024Q3 LIXT Cash Sipc Insured Amount
CashSIPCInsuredAmount
500000 usd
CY2024Q3 us-gaap Legal Fees
LegalFees
45416 usd
CY2023Q3 us-gaap Legal Fees
LegalFees
178012 usd
us-gaap Legal Fees
LegalFees
192239 usd
us-gaap Legal Fees
LegalFees
835362 usd
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_84F_eus-gaap--ConcentrationRiskCreditRisk_zc6L6eHnSRzj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86E_z7sQOG4qI6A">Concentration of Risk</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company periodically contracts with vendors and consultants to provide services related to the Company’s operations. Charges incurred for these services can be for a specific period (typically one year) or for a specific project or task. Costs and expenses incurred that represented <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20240701__20240930__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zaLQ2FR6PBuj"><span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230701__20230930__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zMrg8t5a1n1h">10</span></span>% or more of general and administrative costs or research and development costs for the three months ended September 30, 2024 and 2023 are described below.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General and administrative costs for the three months ended September 30, 2024 and 2023 include charges from legal firms and other vendors for general licensing and patent prosecution costs relating to the Company’s intellectual properties representing <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240701__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zwtZfuBWcZga" title="Concentration risk percentage">7.3</span>% and <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zCQkBYHB9wJa" title="Concentration risk percentage">20.0</span>% of total general and administrative costs, respectively. General and administrative costs for the three months ended September 30, 2024 and 2023 also included charges for the cost of directors and officer’s insurance of <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240701__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__custom--CostOfDirectorsAndOfficersInsuranceMember_z6g0npktpwkj" title="Concentration risk percentage">18.4</span>% and <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__custom--CostOfDirectorsAndOfficersInsuranceMember_zkm1dDCHOWUh" title="Concentration risk percentage">11.9</span>%, respectively, corporate legal fees of <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240701__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__custom--CorporateLegalFeesMember_zReDTOVN1n1b" title="Concentration risk percentage">9.8</span>% and <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__custom--CorporateLegalFeesMember_z9X8nFkEwkvf" title="Concentration risk percentage">10.6</span>%, respectively, and for the fair value of stock options granted to directors and corporate officers representing <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20240701__20240930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__srt--TitleOfIndividualAxis__custom--StockOptionsGrantedtoDirectorsAndCorporateOfficersMember_z2HlgrZN9Rjg" title="Concentration of risk, percentage">17.2</span>% and <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230701__20230930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__srt--TitleOfIndividualAxis__custom--StockOptionsGrantedtoDirectorsAndCorporateOfficersMember_znvkx5DwMQC8" title="Concentration of risk, percentage">12.6</span>%, respectively, of total general and administrative costs.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development costs for the three months ended September 30, 2024 include charges from three vendors and consultants representing <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20240701__20240930__srt--MajorCustomersAxis__custom--VendorAndConsultantOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zLD1zEBzQ54f" title="Concentration of risk, percentage">57.2</span>%, <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20240701__20240930__srt--MajorCustomersAxis__custom--VendorAndConsultantTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zyAqFyNMX4Wl" title="Concentration of risk, percentage">21.1</span>% and <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20240701__20240930__srt--MajorCustomersAxis__custom--VendorAndConsultantThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zok3aJ0AR09f" title="Concentration of risk, percentage">15.1</span>%, respectively, of total research and development costs. Research and development costs for the three months ended September 30, 2023 include charges from four vendors and consultants representing <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230701__20230930__srt--MajorCustomersAxis__custom--VendorAndConsultantOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_z5aJ5evVvwJc" title="Concentration of risk, percentage">38.9</span>%, <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230701__20230930__srt--MajorCustomersAxis__custom--VendorAndConsultantTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zSALD1qZZcZi" title="Concentration of risk, percentage">24.9</span>%, <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230701__20230930__srt--MajorCustomersAxis__custom--VendorAndConsultantThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zCE2JnTTRPY2" title="Concentration of risk, percentage">15.9</span>% and <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230701__20230930__srt--MajorCustomersAxis__custom--VendorAndConsultantFourMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zjYV3tatvjil" title="Concentration of risk, percentage">14.9</span>%, respectively, of total research and development costs.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs and expenses incurred that represented <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20240101__20240930__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_z9r4j1GJaiE8" title="Concentration risk percentage"><span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20230101__20230930__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zQkP9iu10tX8" title="Concentration risk percentage">10</span></span>% or more of general and administrative costs or research and development costs for the nine months ended September 30, 2024 and 2023 are described below.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General and administrative costs for the nine months ended September 30, 2024 and 2023 include charges from legal firms and other vendors for general licensing and patent prosecution costs relating to the Company’s intellectual properties representing <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20240101__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zY3kjQoCnQAh" title="Concentration risk percentage">8.5</span>% and <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20230101__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z5uk1GhU6kWc" title="Concentration risk percentage">25.2</span>% of total general and administrative costs, respectively. General and administrative costs for the nine months ended September 30, 2024 and 2023 also included charges for the cost of directors and officer’s insurance of <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20240101__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__custom--CostOfDirectorsAndOfficersInsuranceMember_z8pIi99QKHLk" title="Concentration risk percentage">16.0</span>% and <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20230101__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__custom--CostOfDirectorsAndOfficersInsuranceMember_zCtFhvGWnGti" title="Concentration risk percentage">9.3</span>%, respectively, corporate legal fees of <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20240101__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__custom--CorporateLegalFeesMember_zzcKZeipimY3" title="Concentration risk percentage">11.5</span>% and <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20230101__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__custom--CorporateLegalFeesMember_zXu4jEkUTW97" title="Concentration risk percentage">7.5</span>%, respectively, and for the fair value of stock options granted to directors and corporate officers representing <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20240101__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__custom--DirectorsAndCorporateOfficersMember_zw3VJ2KsfpC" title="Concentration risk percentage">15.0</span>% and <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20230101__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__custom--DirectorsAndCorporateOfficersMember_z8qVpOzxWxV3" title="Concentration risk percentage">20.2</span>%, respectively, of total general and administrative costs.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development costs for the nine months ended September 30, 2024 include charges from three vendors and consultants representing <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20240101__20240930__srt--MajorCustomersAxis__custom--VendorAndConsultantOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zQjCopyhaEvj" title="Concentration of risk, percentage">41.2</span>%, <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20240101__20240930__srt--MajorCustomersAxis__custom--VendorAndConsultantTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zJQs3exh514c" title="Concentration of risk, percentage">30.4</span>% and <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20240101__20240930__srt--MajorCustomersAxis__custom--VendorAndConsultantThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zfb3d7lz5n0k" title="Concentration of risk, percentage">12.6</span>%, respectively, of total research and development costs. Research and development costs for the nine months ended September 30, 2023 include charges from three vendors and consultants representing <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20230930__srt--MajorCustomersAxis__custom--VendorAndConsultantOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z0XKIzxA4ax8" title="Concentration of risk, percentage">35.9</span>%, <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20230930__srt--MajorCustomersAxis__custom--VendorAndConsultantTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zzBWmaGClbv8" title="Concentration of risk, percentage">21.0</span>%, and <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20230930__srt--MajorCustomersAxis__custom--VendorAndConsultantThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zvwPX0ec7Ba5" title="Concentration of risk, percentage">12.4</span>%, respectively, of total research and development costs.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1504514 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1556178 shares
CY2024Q3 LIXT Foreign Currency Exchange Rate Translation
ForeignCurrencyExchangeRateTranslation
1.0991 pure
CY2023Q3 LIXT Foreign Currency Exchange Rate Translation
ForeignCurrencyExchangeRateTranslation
1.0885 pure
LIXT Foreign Currency Exchange Rate Translation
ForeignCurrencyExchangeRateTranslation
1.0991 pure
LIXT Foreign Currency Exchange Rate Translation
ForeignCurrencyExchangeRateTranslation
1.0839 pure
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
361630 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
132487 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
691402 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
749029 usd
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
361630 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
132487 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
691402 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
749029 usd
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2249290 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2249290 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2249290 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2249290 shares
CY2024Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
808365 shares
CY2021Q2 us-gaap Cash
Cash
40000 usd
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage
SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
0.125 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.3805 pure
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P4Y
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
106827 usd
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
112106 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
340445 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
669146 usd
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
552083 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
15.330
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
92815 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.259
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
21666 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
42.461
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
623232 shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
12.441
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P3Y4M9D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
252292 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
28.387
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
372815 shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
18.305
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P2Y10M13D
us-gaap Deferred Compensation Arrangement With Individual Compensation Expense
DeferredCompensationArrangementWithIndividualCompensationExpense
467000 usd
CY2024Q3 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
623232 shares
CY2024Q3 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
372815 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.87
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0 usd
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
250417 shares
CY2024Q3 us-gaap Other Commitment
OtherCommitment
3616000 usd
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001493152-24-044810-index-headers.html Edgar Link pending
0001493152-24-044810-index.html Edgar Link pending
0001493152-24-044810.txt Edgar Link pending
0001493152-24-044810-xbrl.zip Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
lixt-20240930.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
lixt-20240930_cal.xml Edgar Link unprocessable
lixt-20240930_def.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
lixt-20240930_lab.xml Edgar Link unprocessable
lixt-20240930_pre.xml Edgar Link unprocessable
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable